DB05670InvestigationalProtein Based Therapies
ATL-104 is a potent mitogen for epithelial cells of the gastrointestinal tract. In animal models, ATL-104 aids regeneration of the gastrointestinal tract after treatment with chemotherapeutic agents.
- Primary indication
- Investigated for use/treatment in adverse effects (chemotherapy).Curator reviewed
- Code names
- ATL-104
What you can answer from here — as of April 02, 2025
Which companies are running trials of ATL-104, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account